

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES



AMP Announces Non-Brokered Placement to Raise Growth Capital

ERFURT and BERLIN, Germany – October 1st, 2021, AMP Alternative Medical Products Inc. (Frankfurt: [C4TA](#), ISIN: CA0318961038) (CSE: [XCX](#)) (“AMP”), a pharmaceutical supplier of medical and CBD therapeutic wellness cannabis products to German pharmacies, announces a non-brokered private placement financing to raise up to C\$500,000 priced at C\$0.40 per share. The Company may pay a finder’s fee and warrants to one or more arm’s length parties. All securities issued pursuant to the offering will be subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws.

The Company closed the first tranche of its non-brokered private placement raising gross proceeds of C\$300,000. No finders’ fees were paid.

About AMP

AMP Alternative Medical Products Inc. (formerly AMP German Cannabis Group Inc.) is a supplier of medical cannabis and CBD cannabis products to German pharmacies through its subsidiary AMP Alternative Medical Products GmbH, with offices in Erfurt and Berlin, Germany. AMP operates in accordance with the German Narcotic Drug Act (BtMG) and with the regulatory requirements set by the Free State of Thuringia, ensuring products imported by AMP from around the world and sold in Germany meet the European Union - Good Manufacturing Practice (EU-GMP) standard.

The AMP Roundtable Series discusses issues about medical cannabis in Germany and is available as a podcast and video. In Episode #2, “Politics and Medical Cannabis in Germany” Dr. Wieland Schinnenburg, MdB (FDP), provides an up-to-date overview of the political issues and challenges facing the medical cannabis industry in Germany. Learn more at www.amp-eu.de/roundtable.

To learn more about the European cannabis industry, download AMP’s sponsored report by Prohibition Partners; <https://prohibitionpartners.com/reports/the-european-cannabis-report-6th-edition/>

For more information, please visit www.amp-eu.com

AMP’S CONTACT:

Investor Relations:

Alex Blodgett, CEO and Director

investor@amp-eu.com

+1 236-833-1602

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE AMP Alternative Medical Products Inc.